SCHEMBL25514014

SCHEMBL25514014

Fc1ccc(-n2cc(Br)cn2)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACKR3 P25106 1/20 0.40
PRKCI P41743 1/20 0.40
KDM4E B2RXH2 3/20 0.38
HSD17B10 Q99714 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
PLAU P00749 2/20 0.36
ELANE P08246 2/20 0.36
GAA P10253 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
CFTR P13569 3/20 0.35
TSHR P16473 1/20 0.34
SPR P35270 2/20 0.34
ALDH1A1 P00352 3/20 0.33
NPC1 O15118 2/20 0.33
HPGD P15428 2/20 0.33
RAB9A P51151 1/20 0.33
MAPT P10636 1/20 0.33
XBP1 P17861 1/20 0.33
CYP46A1 Q9Y6A2 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15332939 0.80 ALDH1A1 (0.37) ACKR3PRKCIKDM4EHSD17B10RXFP1
SCHEMBL15331462 0.80 ALDH1A1 (0.48) ACKR3PRKCIKDM4EPLAUELANE
SCHEMBL10264757 0.79 TDO2 (0.44) ACKR3KDM4ESIGMAR1ALDH1A1NPC1
SCHEMBL4565600 0.79 ACKR3 (0.40) ACKR3KDM4EGAASIGMAR1CFTR
SCHEMBL14947695 0.79 GRM4 (0.48) PRKCIPLAUELANEGAAALDH1A1
SCHEMBL17180076 0.76 PRKCI (0.50) PRKCIKDM4EPLAUELANEALDH1A1
SCHEMBL20162969 0.76 P2RX7 (0.38) ACKR3SIGMAR1CFTRTSHRMAPT
SCHEMBL2609426 0.76 CFTR (0.43) ACKR3SIGMAR1CFTRNPC1RAB9A
SCHEMBL19902125 0.76 NPC1 (0.46) ACKR3NPC1RAB9A
SCHEMBL20162925 0.76 SCD (0.44) ACKR3GAASIGMAR1CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339936-A1 COMPOUND HAVING KINASE INHIBITORY ACTIVITY CYTOSINLAB THERAPEUTICS CO., LTD. (CN) 2023-10-26 US disclosed
EP-4186901-A1 COMPOUND HAVING KINASE INHIBITORY ACTIVITY Cytosinlab Therapeutics Co., Ltd. (CN) 2023-05-31 EP disclosed
US-20230063230-A1 NURR1 RECEPTOR MODULATORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-02 US disclosed
CN-113692276-A NURR1 receptor modulators 加利福尼亚大学董事会 2021-11-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230063230-A1 NURR1 RECEPTOR MODULATORS NR2E3, NR4A2, NR0B1 ACKR3 1249/4885PRKCI 4152/4885KDM4E 3995/4885
US-20230339936-A1 COMPOUND HAVING KINASE INHIBITORY ACTIVITY FLT3, ERBB2, ABL1 ACKR3 697/4885PRKCI 254/4885KDM4E 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.